In what would be a big boost for the nationwide COVID-19 vaccination programme, Hyderabad-based Biological E's upcoming COVID-19 vaccine Corbevax is likely to be the most affordable vaccine in India upon launch after it gets the emergency use authorisation (EUA), reports Times of India.
In an interview with Times of India, the company's managing director Mahima Datla is said to have hinted that both the doses of the receptor binding domain protein vaccine could be priced at a sub-Rs 500 level and that the price may even be lower than Rs 400 for two doses.
The Corbevax vaccine is presently undergoing the third stage clinical trials and has shown promising results in Phase I and Phase II trials.
It should also be noted that the government has already made an advanced payment of Rs 1,500 crore to the company for pre-booking 30 crore doses. This brings down the price per dose to just Rs 50.
The company has already begun the at-risk manufacturing of the vaccine over the last month or so and is likely to begin full-fledged production of 75-80 million doses per month from August onwards.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.